Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 82

1.

A nationwide survey of mortality in acromegaly.

Kauppinen-Mäkelin R, Sane T, Reunanen A, Välimäki MJ, Niskanen L, Markkanen H, Löyttyniemi E, Ebeling T, Jaatinen P, Laine H, Nuutila P, Salmela P, Salmi J, Stenman UH, Viikari J, Voutilainen E.

J Clin Endocrinol Metab. 2005 Jul;90(7):4081-6. Epub 2005 May 10.

PMID:
15886256
2.

Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly.

Ayuk J, Clayton RN, Holder G, Sheppard MC, Stewart PM, Bates AS.

J Clin Endocrinol Metab. 2004 Apr;89(4):1613-7.

PMID:
15070920
3.

Assessment of disease activity in treated acromegalic patients using a sensitive GH assay: should we achieve strict normal GH levels for a biochemical cure?

Costa AC, Rossi A, Martinelli CE Jr, Machado HR, Moreira AC.

J Clin Endocrinol Metab. 2002 Jul;87(7):3142-7.

PMID:
12107214
4.

GH and mortality in acromegaly.

Sheppard MC.

J Endocrinol Invest. 2005;28(11 Suppl International):75-7. Review.

PMID:
16625851
5.

Factors influencing mortality in acromegaly.

Holdaway IM, Rajasoorya RC, Gamble GD.

J Clin Endocrinol Metab. 2004 Feb;89(2):667-74.

PMID:
14764779
6.

Quality of life in treated patients with acromegaly.

Kauppinen-Mäkelin R, Sane T, Sintonen H, Markkanen H, Välimäki MJ, Löyttyniemi E, Niskanen L, Reunanen A, Stenman UH.

J Clin Endocrinol Metab. 2006 Oct;91(10):3891-6. Epub 2006 Jul 18.

PMID:
16849407
7.

Ten-year follow-up results of transsphenoidal microsurgery in acromegaly.

Biermasz NR, van Dulken H, Roelfsema F.

J Clin Endocrinol Metab. 2000 Dec;85(12):4596-602.

PMID:
11134114
8.

A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly.

Holdaway IM, Bolland MJ, Gamble GD.

Eur J Endocrinol. 2008 Aug;159(2):89-95. doi: 10.1530/EJE-08-0267. Epub 2008 Jun 4.

9.

Successful mortality reduction and control of comorbidities in patients with acromegaly followed at a highly specialized multidisciplinary clinic.

Mercado M, Gonzalez B, Vargas G, Ramirez C, de los Monteros AL, Sosa E, Jervis P, Roldan P, Mendoza V, López-Félix B, Guinto G.

J Clin Endocrinol Metab. 2014 Dec;99(12):4438-46. doi: 10.1210/jc.2014-2670.

PMID:
25210882
10.

Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size.

Bevan JS, Atkin SL, Atkinson AB, Bouloux PM, Hanna F, Harris PE, James RA, McConnell M, Roberts GA, Scanlon MF, Stewart PM, Teasdale E, Turner HE, Wass JA, Wardlaw JM.

J Clin Endocrinol Metab. 2002 Oct;87(10):4554-63.

PMID:
12364434
11.
12.

Conventional pituitary irradiation is effective in lowering serum growth hormone and insulin-like growth factor-I in patients with acromegaly.

Jenkins PJ, Bates P, Carson MN, Stewart PM, Wass JA.

J Clin Endocrinol Metab. 2006 Apr;91(4):1239-45. Epub 2006 Jan 10.

PMID:
16403824
13.

Hormonal and metabolic effects of radiotherapy in acromegaly: long-term results in 128 patients followed in a single center.

Barrande G, Pittino-Lungo M, Coste J, Ponvert D, Bertagna X, Luton JP, Bertherat J.

J Clin Endocrinol Metab. 2000 Oct;85(10):3779-85.

PMID:
11061538
14.

Excess mortality in acromegaly.

Holdaway IM.

Horm Res. 2007;68 Suppl 5:166-72. doi: 10.1159/000110617. Epub 2007 Dec 10. Review.

PMID:
18174739
15.

ACTH deficiency, higher doses of hydrocortisone replacement, and radiotherapy are independent predictors of mortality in patients with acromegaly.

Sherlock M, Reulen RC, Alonso AA, Ayuk J, Clayton RN, Sheppard MC, Hawkins MM, Bates AS, Stewart PM.

J Clin Endocrinol Metab. 2009 Nov;94(11):4216-23. doi: 10.1210/jc.2009-1097. Epub 2009 Oct 6.

PMID:
19808848
16.

Could different treatment approaches in acromegaly influence life expectancy? A comparative study between Bulgaria and Campania (Italy).

Colao A, Vandeva S, Pivonello R, Grasso LF, Nachev E, Auriemma RS, Kalinov K, Zacharieva S.

Eur J Endocrinol. 2014 Aug;171(2):263-73. doi: 10.1530/EJE-13-1022. Epub 2014 May 30.

17.

The implication of somatotroph adenoma phenotype to somatostatin analog responsiveness in acromegaly.

Bhayana S, Booth GL, Asa SL, Kovacs K, Ezzat S.

J Clin Endocrinol Metab. 2005 Nov;90(11):6290-5. Epub 2005 Aug 23.

PMID:
16118335
18.

Long-term follow-up results of postoperative radiotherapy in 36 patients with acromegaly.

Biermasz NR, van Dulken H, Roelfsema F.

J Clin Endocrinol Metab. 2000 Jul;85(7):2476-82.

PMID:
10902796
19.

Monitoring disease activity using GH and IGF-I in the follow-up of 501 patients with acromegaly.

Sherlock M, Aragon Alonso A, Reulen RC, Ayuk J, Clayton RN, Holder G, Sheppard MC, Bates A, Stewart PM.

Clin Endocrinol (Oxf). 2009 Jul;71(1):74-81. doi: 10.1111/j.1365-2265.2008.03461.x. Epub 2008 Oct 26.

PMID:
19178529
20.

Influence of growth hormone receptor d3 and full-length isoforms on biochemical treatment outcomes in acromegaly.

Bianchi A, Giustina A, Cimino V, Pola R, Angelini F, Pontecorvi A, De Marinis L.

J Clin Endocrinol Metab. 2009 Jun;94(6):2015-22. doi: 10.1210/jc.2008-1337. Epub 2009 Mar 31.

PMID:
19336510

Supplemental Content

Support Center